VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
SIGA
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
SIGASIGA Technologies, Inc.
$3.67$263M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders

SIGA logoSIGA Technologies, Inc.(SIGA)Earnings, Financials & Key Ratios

SIGA•NASDAQ
$3.67
11.1× P/E·Price updated Jul 7, 2026
SectorHealthcareIndustrySpecialty & Generic PharmaSub-IndustryVaccines and biodefense products
AboutSIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security and infectious disease markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. SIGA Technologies, Inc. has a strategic partnership with Cipla Therapeutics to deliver sustained innovation and access to antibacterial drugs primarily against biothreats. The company was incorporated in 1995 and is headquartered in New York, New York.Show more
  • Revenue$95M-31.8%
  • EBITDA$24M-65.6%
  • Net Income$23M-60.7%
  • EPS (Diluted)0.33-60.2%
  • Gross Margin68.57%-11.5%
  • EBITDA Margin25.65%-49.6%
  • Operating Margin25.05%-50.3%
  • Net Margin24.63%-42.3%
  • ROE11.24%-60.8%

SIGA Price & Volume

SIGA Technologies, Inc. (SIGA) stock price & volume — 10-year historical chart

Loading chart...

Episodic Procurement Cycles Drive Extreme Financial Volatility

Investment Thesis • Updated 2026Q1

VerdictNegative
Growth:Contracting
Profitability:Strained
Financial:Fortress
Cash Flow:Deteriorating
Primary Risk:Lumpy government procurement dependency

Key Thesis Takeaways

  • SIGA Technologies remains fundamentally tethered to the unpredictable timing of government biodefense procurement, creating a boom-bust cycle that obscures long-term value.
  • While the company maintains a fortress balance sheet with zero long-term debt, the lack of diversified revenue streams beyond TPOXX leaves the firm highly vulnerable to federal policy shifts.
  • Investors should exercise caution as the current negative operating margin of 85.2% and eroding retained earnings of -$90.4 million suggest that the business model struggles to achieve sustainable profitability outside of specific delivery milestones.

Verdict Logic

the company's reliance on lumpy government contracts is reflected in a forward P/E of 2.31, which suggests the market is pricing in significant risk regarding the sustainability of future revenue recognition.

SIGA Growth Metrics

SIGA Technologies, Inc. (SIGA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years27.74%
5 Years-5.41%
3 Years-5.13%
TTM-22.06%

Profit CAGR

10 Years-
5 Years-16.19%
3 Years-11.75%
TTM-58.25%

EPS CAGR

10 Years-
5 Years-14.21%
3 Years-10.48%
TTM-59.26%

Return on Capital

10 Years41.84%
5 Years33.67%
3 Years29.8%
Last Year11.27%

SIGA Recent Earnings

SIGA Technologies, Inc. (SIGA) EPS & revenue vs analyst estimates — last 4 quarters

Full history →
●Beat Revenue 0/12 qtrs (0%)
Q2 2026Latest
May 7, 2026
Metric
Actual
Est
EPS
$0.05
—
Rev
$6M
—
Q2 2026
Mar 10, 2026
Metric
Actual
Est
EPS
$0.08
—
Rev
$4M
—
Q4 2025
Nov 6, 2025
Metric
Actual
Est
EPS
$0.09
—
Rev
$3M
—
Q3 2025
Aug 5, 2025
Metric
Actual
Est
EPS
$0.49
—
Rev
$81M
—
QuarterDateEPS (Act vs Est)Revenue (Act vs Est)
Q2 2026LatestMay 7, 2026
$0.05
$6M
Q2 2026Mar 10, 2026
$0.08
$4M
Q4 2025Nov 6, 2025
$0.09
$3M
Q3 2025Aug 5, 2025
$0.49
$81M
Based on last 12 quarters of dataView full earnings history →

Peers Comparison

Key metrics vs top competitors for SIGA Technologies, Inc. (SIGA)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
SIGA logoSIGASIGA Technologies, Inc.Current
$3.67$263.23M11.12-31.8%24.63%11.24%16.41%
GILD logoGILDGilead Sciences, Inc.
$136.36$169.3B20.112.39%30.99%42.33%—
AVTX logoAVTXAvalo Therapeutics, Inc.
$19.25$217.41M-3.30-86.62%-143627.12%-97.55%—
AGEN logoAGENAgenus Inc.
$3.50$145.75M-1029.4110.37%52.16%——
VRTX logoVRTXVertex Pharmaceuticals Incorporated
$522.25$132.84B34.099.57%35.4%23.93%—
REGN logoREGNRegeneron Pharmaceuticals, Inc.
$676.23$70.26B16.300.99%29.65%14.32%—

Compare SIGA vs Peers

SIGA Technologies, Inc. (SIGA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs GILD

Most directly comparable listed peer for SIGA.

Scale Benchmark

vs VRTX

Larger-name benchmark to compare SIGA against a more recognizable public peer.

Peer Set

Compare Top 5

vs GILD, AVTX, AGEN, VRTX

SIGA SEC Filings & Documents

SIGA Technologies, Inc. (SIGA) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

May 7, 2026·SEC

Material company update

Mar 26, 2026·SEC

Material company update

Mar 10, 2026·SEC

10-K Annual Reports

4
FY 2026

Mar 10, 2026·SEC

FY 2025

Mar 11, 2025·SEC

FY 2024

Mar 12, 2024·SEC

10-Q Quarterly Reports

6
FY 2026

May 7, 2026·SEC

FY 2025

Nov 6, 2025·SEC

FY 2025

Aug 5, 2025·SEC

Get notified when SIGA posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

SIGA Frequently Asked Questions

SIGA Technologies, Inc. (SIGA) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is SIGA Technologies, Inc.'s revenue?

SIGA Technologies, Inc. (SIGA) reported $93.8M in revenue for fiscal year 2025. This represents a 93683% increase from $0.1M in 1996.

How fast is SIGA Technologies, Inc. growing?

SIGA Technologies, Inc. (SIGA) saw revenue decline by 31.8% over the past year.

Is SIGA profitable?

Yes, SIGA Technologies, Inc. (SIGA) is profitable, generating $20.3M in net income for fiscal year 2025 (24.6% net margin).

Dividend & Returns
Does SIGA pay dividends?

Yes, SIGA Technologies, Inc. (SIGA) pays a dividend with a yield of 16.41%. This makes it attractive for income-focused investors.

What is SIGA's return on equity?

SIGA Technologies, Inc. (SIGA) has a return on equity (ROE) of 11.2%. This is reasonable for most industries.

What is SIGA Technologies, Inc.'s free cash flow?

SIGA Technologies, Inc. (SIGA) generated $27.4M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

What if you invested $1,000 in SIGA back in 1996?

Total return calculator · dividends reinvested · 30+ years of data

See returns →